- Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up
-
Lacquaniti A, Pasqualetti P, Tocco TCd, Campo S, Rovito S, Bucca M, Ragusa A, Monardo P
- KMID: 2507094
- Kidney Res Clin Pract.
- 2020 Sep;39(3):334-343.
- doi: 10.23876/j.krcp.20.015
Background: Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results... -
- CITED
-
- Close
- SHARE
-
- Close
